BioLytical

The Florida Department of Health, Bureau of Communicable Disease, HIV/AIDS Section, has initiated a single-source acquisition under Chapter 60A-1.045, F.A.C. to procure INSTI HIV-1/HIV-2 Antibody Tests from BioLytical Laboratories Inc. This procurement is driven by the urgent public health need for rapid HIV detection, as the INSTI test is the only FDA-approved rapid assay capable of detecting antibodies up to nine days earlier than the Western Blot, enabling timely medical intervention and transmission prevention. The contract is for a one-year term with an estimated value of $75,000 and is identified by solicitation number EXP2684 under NAICS code 41116164 for laboratory test kits. The deliverable consists exclusively of the INSTI HIV-1/HIV-2 Antibody Tests, which provide results in 60 seconds and are required to meet FDA approval standards. The procurement is non-competitive, justified solely on the unique performance characteristics of the product, with no evaluation factors, inspection criteria, or packaging specifications defined. All inquiries must be directed to Yasemin Sulker at the Florida Department of Health in Tallahassee, and proposals were due by July 10, 2026, though the solicitation was canceled on June 18, 2026. The action was posted in compliance with Florida Statutes Sections 120.57(3) and 287.057(3), fulfilling public notice requirements for single-source acquisitions.